1
Participants
Start Date
January 7, 2019
Primary Completion Date
April 30, 2019
Study Completion Date
April 14, 2020
Rogaratinib (BAY1163877)
Rogaratinib will be administered on 20 days in Cycle 1 (single dosing on Day 1 and twice daily dosing on Days 3-21). In Cycles ≥2, rogaratinib will be administered twice daily for 21 days, with cycles repeated every 21 days. Treatment will be continued until death, tumor progression, unacceptable toxicity, consent withdrawal, or until another criterion is met for withdrawal from the study at the discretion of the investigator.
Beijing Hospital, Beijing
Lead Sponsor
Bayer
INDUSTRY